SpringWorks Therapeutics’ chief people officer sells $1.6 million in stock

Daniel Pichl, Chief People Officer at SpringWorks Therapeutics (NASDAQ:SWTX), has recently sold a significant portion of his holdings in the company. According to a Form 4 filing with the SEC, Pichl sold 29,750 shares of common stock on February 10, 2025, generating approximately $1.6 million. The shares were sold at prices ranging from $53.018 to $57.1531. The timing is notable as the stock trades near its 52-week high of $60, having surged over 50% in the past week alone, according to InvestingPro data.

In addition to the sales, Pichl also exercised stock options, acquiring 29,750 shares at a price of $27.64 per share. Following these transactions, Pichl holds a total of 50,762 shares directly. With the stock’s technical indicators suggesting overbought conditions and earnings scheduled for February 20, investors seeking deeper insights can access 14 additional key metrics through InvestingPro.

These transactions were conducted under a pre-arranged trading plan, as per Rule 10b5-1, adopted on May 21, 2024.

In other recent news, SpringWorks Therapeutics has been under the spotlight for several key developments. The company has received FDA approval for their drug, GOMEKLI, designed to treat neurofibromatosis type 1 with symptomatic plexiform neurofibromas. This approval, which is based on the positive results of the Phase 2b ReNeu trial, is a significant milestone for SpringWorks. This achievement is further amplified by the fact that this is their second FDA approval in less than 18 months.

Additionally, analysts from TD Cowen have increased their price target for SpringWorks Therapeutics to $66.00, maintaining a "Buy" rating on the stock. This adjustment takes into account the anticipated European Union approval and launch of GOMEKLI in late 2025.

In merger news, Merck (NSE:PROR) KGaA is in advanced talks to potentially acquire SpringWorks Therapeutics. No legally binding agreement has been reached yet, and critical conditions for the deal are still pending.

Finally, analysts from Guggenheim and Evercore ISI have maintained a positive outlook on SpringWorks Therapeutics. Guggenheim has adjusted the company’s price target to $78, while Evercore ISI has initiated coverage on the company with an Outperform rating and a price target of $60.00. These recent developments mark a significant period for SpringWorks Therapeutics.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.